AMAG Pharmaceuticals announced the acquisition of women?s health brand, Lumara Health, for $675 million, with an additional contingency of up to $350 million.
AMAG Pharmaceuticals announced on Sept. 29, 2014 that is has entered an agreement to acquire Lumara Health for $675 million, offering an additional $350 million based on milestone achievements.
Lumara Health specializes in women’s health pharmaceuticals throughout the stages of a woman’s life, with a focus on maternal health. Within the agreement, AMAG acquires Makena (hydroxyprogesterone caproate injection), Lumara’s FDA-approved drug to reduce the risk of preterm birth in women who have already had a premature baby and are currently pregnant.
"This is a truly transformative transaction that will propel AMAG into a profitable, high-growth multi-product specialty pharmaceutical company positioned for what we expect to be continued revenue and bottom-line growth, further business diversification, and shareholder value creation,” said William Heiden, president and CEO of AMAG.
